<p>Annexon（納斯達克股票代碼：ANNX - 獲取免費報告）於週四公佈了季度財報。該公司報告季度每股收益為（$0.23），超出市場共識預期的（$0.30）$0.07，FiscalAI 報道。</p>
<h2>Annexon 股票表現</h2>
<p>週四，納斯達克 ANNX 的交易價格下跌了 $0.18，達到 $5.52。該公司的股票交易量為 2,357,564 股，而其平均交易量為 2,106,709 股。該公司的市值為 $897.06 百萬，市盈率為 -4.06，貝塔係數為 1.22。Annexon 的 12 個月最低價為 $1.60，最高價為 $7.18。該公司的 50 日移動平均價格為 $5.69，200 日移動平均價格為 $5.08。</p>
<h2>分析師設定新目標價</h2>
<p>幾位股票研究分析師最近對 ANNX 股票發表了評論。Cantor Fitzgerald 在 1 月 14 日的研究報告中重申了對 Annexon 股票的 “增持” 評級。Chardan Capital 在 3 月 20 日的研究報告中重申了 “買入” 評級，並設定了 $16.00 的目標價。最後，Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Annexon 股票的 “賣出（d-）” 評級。五位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Annexon 目前的平均評級為 “適度買入”，共識目標價為 $17.00。</p>
<p><strong>獲取我們關於 Annexon 的最新股票報告</strong></p>
<h2>內部人士買賣</h2>
<p>在其他 Annexon 的新聞中，執行副總裁 Ted Yednock 於 2 月 18 日出售了 7,857 股 Annexon 股票。股票以平均價格 $5.11 出售，總價值為 $40,149.27。交易後，該執行副總裁直接持有 97,227 股公司股票，價值約 $496,829.97。此次交易使其持股比例減少了 7.48%。該交易已在向 SEC 提交的文件中披露，可以通過此超鏈接訪問。此外，執行副總裁 Dean Richard Artis 於 2 月 18 日出售了 5,290 股 Annexon 股票。股票以平均價格 $5.10 出售，總交易額為 $26,979.00。交易完成後，該執行副總裁持有 123,487 股公司股票，價值約 $629,783.70。這代表其持股比例減少了 4.11%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士在上個季度共出售了價值 $165,973 的 32,513 股公司股票。公司內部人士持有公司股票的 11.87%。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者最近買賣了該公司的股票。Landscape Capital Management L.L.C. 在第四季度以 $50,000 的估值收購了 Annexon 的新股份。CIBC Bancorp USA Inc. 在第三季度以約 $31,000 的價格收購了 Annexon 的新股份。Mercer Global Advisors Inc. ADV 在第四季度以約 $52,000 的價格收購了 Annexon 的新股份。Engineers Gate Manager LP 在第二季度以約 $32,000 的價格收購了 Annexon 的新股份。最後，Cerity Partners LLC 在第四季度以約 $74,000 的價格收購了 Annexon 的新股份。</p>
<h2>關於 Annexon</h2>
<p>（獲取免費報告）</p>
<p>Annexon Inc 是一家臨牀階段的生物技術公司，專注於為神經退行性和神經免疫疾病患者發現和開發靶向補體的療法。該公司的研究平台集中在抑制 C1 複合體，這是經典補體途徑的關鍵啓動因子，涉及多種罕見且危及生命的疾病。通過選擇性地靶向上遊補體激活，Annexon 旨在防止異常的免疫介導損傷，這種損傷是吉蘭 - 巴雷綜合症（GBS）和自身免疫性神經病等疾病的特徵。</p>
<p>Annexon 的管線核心是 ANX005，這是一種針對 C1q 亞單位的人源化單克隆抗體，目前正在進行急性 GBS 和慢性神經退行性疾病的二期臨牀試驗。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Annexon 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Annexon 嗎？</h2>
<p>在你考慮 Annexon 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Annexon 並不在名單上。</p>
<p>雖然 Annexon 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ANNX

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 3 倍做多 - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

IBBQ

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

<p>Annexon（納斯達克代碼：ANNX）報告的季度收益為每股虧損 0.23 美元，超出預期 0.07 美元。該股交易下跌至 5.52 美元，市值為 8.9706 億美元。分析師的評級各不相同，五位推薦買入，一位推薦賣出。近期內部人士出售了 32,513 股。機構投資者也表現出興趣，獲得了新頭寸。Annexon 專注於針對神經退行性疾病的補體靶向療法，其主要產品 ANX005 正在進行第二階段臨牀試驗</p>

<p>Annexon (NASDAQ:ANNX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07, FiscalAI reports.</p>
<div class="lb-trans"><p>Annexon（納斯達克股票代碼：ANNX - 獲取免費報告）於週四公佈了季度財報。該公司報告季度每股收益為（$0.23），超出市場共識預期的（$0.30）$0.07，FiscalAI 報道。</p>
</div><h2>Annexon Stock Performance</h2>
<div class="lb-trans"><h2>Annexon 股票表現</h2>
</div><p>NASDAQ ANNX traded down $0.18 during trading on Thursday, reaching $5.52. The company's stock had a trading volume of 2,357,564 shares, compared to its average volume of 2,106,709. The firm has a market cap of $897.06 million, a price-to-earnings ratio of -4.06 and a beta of 1.22. Annexon has a twelve month low of $1.60 and a twelve month high of $7.18. The business's fifty day moving average price is $5.69 and its 200-day moving average price is $5.08.</p>
<div class="lb-trans"><p>週四，納斯達克 ANNX 的交易價格下跌了 $0.18，達到 $5.52。該公司的股票交易量為 2,357,564 股，而其平均交易量為 2,106,709 股。該公司的市值為 $897.06 百萬，市盈率為 -4.06，貝塔係數為 1.22。Annexon 的 12 個月最低價為 $1.60，最高價為 $7.18。該公司的 50 日移動平均價格為 $5.69，200 日移動平均價格為 $5.08。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several equities research analysts recently commented on ANNX shares. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Annexon in a research note on Wednesday, January 14th. Chardan Capital reiterated a &#34;buy&#34; rating and set a $16.00 price target on shares of Annexon in a research note on Friday, March 20th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Annexon in a research note on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Annexon presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.00.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對 ANNX 股票發表了評論。Cantor Fitzgerald 在 1 月 14 日的研究報告中重申了對 Annexon 股票的 “增持” 評級。Chardan Capital 在 3 月 20 日的研究報告中重申了 “買入” 評級，並設定了 $16.00 的目標價。最後，Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Annexon 股票的 “賣出（d-）” 評級。五位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Annexon 目前的平均評級為 “適度買入”，共識目標價為 $17.00。</p>
</div><p><strong>Get Our Latest Stock Report on Annexon</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Annexon 的最新股票報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other Annexon news, EVP Ted Yednock sold 7,857 shares of Annexon stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total value of $40,149.27. Following the transaction, the executive vice president directly owned 97,227 shares in the company, valued at approximately $496,829.97. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Dean Richard Artis sold 5,290 shares of Annexon stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $26,979.00. Following the completion of the transaction, the executive vice president owned 123,487 shares in the company, valued at approximately $629,783.70. This represents a 4.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 32,513 shares of company stock valued at $165,973 in the last quarter. Corporate insiders own 11.87% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Annexon 的新聞中，執行副總裁 Ted Yednock 於 2 月 18 日出售了 7,857 股 Annexon 股票。股票以平均價格 $5.11 出售，總價值為 $40,149.27。交易後，該執行副總裁直接持有 97,227 股公司股票，價值約 $496,829.97。此次交易使其持股比例減少了 7.48%。該交易已在向 SEC 提交的文件中披露，可以通過此超鏈接訪問。此外，執行副總裁 Dean Richard Artis 於 2 月 18 日出售了 5,290 股 Annexon 股票。股票以平均價格 $5.10 出售，總交易額為 $26,979.00。交易完成後，該執行副總裁持有 123,487 股公司股票，價值約 $629,783.70。這代表其持股比例減少了 4.11%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士在上個季度共出售了價值 $165,973 的 32,513 股公司股票。公司內部人士持有公司股票的 11.87%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Landscape Capital Management L.L.C. acquired a new position in Annexon in the fourth quarter valued at $50,000. CIBC Bancorp USA Inc. acquired a new position in shares of Annexon during the third quarter worth about $31,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Annexon during the fourth quarter worth about $52,000. Engineers Gate Manager LP acquired a new position in shares of Annexon during the second quarter worth about $32,000. Finally, Cerity Partners LLC acquired a new position in shares of Annexon during the fourth quarter worth about $74,000.</p>
<div class="lb-trans"><p>機構投資者最近買賣了該公司的股票。Landscape Capital Management L.L.C. 在第四季度以 $50,000 的估值收購了 Annexon 的新股份。CIBC Bancorp USA Inc. 在第三季度以約 $31,000 的價格收購了 Annexon 的新股份。Mercer Global Advisors Inc. ADV 在第四季度以約 $52,000 的價格收購了 Annexon 的新股份。Engineers Gate Manager LP 在第二季度以約 $32,000 的價格收購了 Annexon 的新股份。最後，Cerity Partners LLC 在第四季度以約 $74,000 的價格收購了 Annexon 的新股份。</p>
</div><h2>About Annexon</h2>
<div class="lb-trans"><h2>關於 Annexon</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.</p>
<div class="lb-trans"><p>Annexon Inc 是一家臨牀階段的生物技術公司，專注於為神經退行性和神經免疫疾病患者發現和開發靶向補體的療法。該公司的研究平台集中在抑制 C1 複合體，這是經典補體途徑的關鍵啓動因子，涉及多種罕見且危及生命的疾病。通過選擇性地靶向上遊補體激活，Annexon 旨在防止異常的免疫介導損傷，這種損傷是吉蘭 - 巴雷綜合症（GBS）和自身免疫性神經病等疾病的特徵。</p>
</div><p>At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.</p>
<div class="lb-trans"><p>Annexon 的管線核心是 ANX005，這是一種針對 C1q 亞單位的人源化單克隆抗體，目前正在進行急性 GBS 和慢性神經退行性疾病的二期臨牀試驗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Annexon</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Annexon 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ANNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Annexon Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Annexon 嗎？</h2>
</div><p>Before you consider Annexon, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Annexon 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Annexon 並不在名單上。</p>
</div><p>While Annexon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Annexon 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Annexon (NASDAQ:ANNX) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Market Beat

Annexon

Invesco Nasdaq Biotechnology ETF

Annexon（NASDAQ:ANNX）公佈季度財報，每股收益超出預期 0.07 美元